Background: Stereotactic body radiotherapy (SBRT) and elective nodal radiotherapy (ENRT) are being investigated as metastasis-directed treatments in oligorecurrent prostate cancer (PC); however, comparative data are still lacking.
Objective: To compare outcome and toxicity between both treatments. Primary endpoint was metastasis-free survival, adjusted for selected variables (aMFS).
Design, setting, and participants: This was a multi-institutional, retrospective analysis of 506 (SBRT: 309, ENRT: 197) patients with hormone-sensitive nodal oligorecurrent PC (five or fewer lymph nodes (LNs; N1/M1a), treated between 2004 and 2017. Median follow-up was 36 mo (interquartile range 23-56).
Intervention: SBRT was defined as a minimum of 5 Gy per fraction to each lesion with a maximum of 10 fractions. ENRT was defined as a minimum dose of 45 Gy in up to 25 fractions to the elective nodes, with or without a simultaneous boost to the suspicious node(s). The choice of radiotherapy (RT) was at the discretion of the treating physician, with treatments being unbalanced over the centers.
Outcome measurements and statistical analysis: In total, 506 patients from 15 different treatment centers were included. Primary treatment was radical prostatectomy, RT, or their combination. Nodal recurrences were detected by positron emission tomography/computer tomography (97%) or conventional imaging (3%). Descriptive statistics was used to summarize patient characteristics.
Results and limitations: ENRT was associated with fewer nodal recurrences compared with SBRT (p < 0.001). In a multivariable analysis, patients with one LN at recurrence had longer aMFS after ENRT (hazard ratio: 0.50, 95% confidence interval 0.30-0.85, p = 0.009). Late toxicity was higher after ENRT compared with that after SBRT (16% vs. 5%, p < 0.01). Limitations include higher use of hormone therapy in the ENRT cohort and nonstandardized follow-up.
Conclusions: ENRT reduces the number of nodal recurrences as compared with SBRT, however at higher toxicity. Our findings hypothesize that ENRT should be preferred to SBRT in the treatment of nodal oligorecurrences. This hypothesis needs to be evaluated in a randomized trial.
Patient summary: This study investigated the difference between stereotactic and elective nodal radiotherapy in treating limited nodal metastatic prostate cancer. Nodal relapse was less frequent following elective nodal radiotherapy than following stereotactic body radiotherapy, and thus elective nodal radiotherapy might be the preferred treatment.
Keywords: Elective nodal radiotherapy; Metastasis-directed therapy; Oligometastasis; Oligorecurrence; Prostatic neoplasms; Radiotherapy; Recurrence; Stereotactic ablative body radiotherapy; Stereotactic body radiotherapy.
Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates.Eur Urol. 2019 May;75(5):826-833. doi: 10.1016/j.eururo.2018.10.044. Epub 2018 Nov 29. Eur Urol. 2019. PMID: 30503072
Oligorecurrent Nodal Prostate Cancer: Long-term Results of an Elective Nodal Irradiation Approach.Am J Clin Oncol. 2018 Oct;41(10):960-962. doi: 10.1097/COC.0000000000000419. Am J Clin Oncol. 2018. PMID: 29315174
Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.Eur Urol Focus. 2017 Dec;3(6):538-544. doi: 10.1016/j.euf.2017.07.006. Epub 2017 Aug 8. Eur Urol Focus. 2017. PMID: 28801240
Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row : Nodal oligorecurrent prostate cancer.World J Urol. 2019 Dec;37(12):2607-2613. doi: 10.1007/s00345-018-2322-7. Epub 2018 May 11. World J Urol. 2019. PMID: 29752513 Review.
Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?Cancer Radiother. 2014 Oct;18(5-6):524-34. doi: 10.1016/j.canrad.2014.07.153. Epub 2014 Sep 2. Cancer Radiother. 2014. PMID: 25192626 Review.
Cited by 1 article
Recent advances of PET imaging in clinical radiation oncology.Radiat Oncol. 2020 Apr 21;15(1):88. doi: 10.1186/s13014-020-01519-1. Radiat Oncol. 2020. PMID: 32317029 Free PMC article. Review.